This newsletter presents you the following best read key sessions:
1. Podcast with Dr. Fatima Cardoso about the results of the phase 3 KEYNOTE-756 trial: Neoadjuvant
pembrolizumab plus chemotherapy followed by adjuvant endocrine therapy and pembrolizumab in
early-stage ER+/HER2- breast cancer
2. Perioperative nivolumab combined with neoadjuvant chemotherapy significantly improves the event-free
survival of patients with resectable non-small cell lung cancer
3. Improved clinical outcomes with [177Lu]Lu-PSMA-617 in taxane-naïve patients with metastatic castration-
resistant prostate cancer
4. Induction chemotherapy prior to chemoradiotherapy improves the survival of patients with locally advanced
cervical cancer
5. Datopotamab deruxtecan improves efficacy outcomes and safety in patients with advanced or metastatic
non-squamous non-small cell lung cancer